Literature DB >> 11234777

Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation.

E Vafiadaki1, A Reis, S Keers, R Harrison, L V Anderson, T Raffelsberger, S Ivanova, H Hoger, R E Bittner, K Bushby, R Bashir.   

Abstract

The SJL mouse strain has been widely used as an animal model for experimental autoimmune encephalitis (EAE), inflammatory muscle disease and lymphomas and has also been used as a background strain for the generation of animal models for a variety of diseases including motor neurone disease, multiple sclerosis and atherosclerosis. Recently the SJL mouse was shown to have myopathy due to dysferlin deficiency, so that it can now be considered a natural animal model for limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM). We have cloned the mouse dysferlin cDNA and analysis of the sequence shows that the mouse dysferlin gene is characterized by six C2 domain sequences and a C-terminal anchoring domain, with the human and the mouse dysferlin genes sharing > 90% sequence homology overall. Genomic analysis of the SJL mutation confirms that the 171 bp RNA deletion has arisen by exon skipping resulting from a splice site mutation. The identification of this mutation has implications for the various groups using this widely available mouse stock.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11234777     DOI: 10.1097/00001756-200103050-00039

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

Review 1.  Membrane repair and immunological danger.

Authors:  Norma W Andrews
Journal:  EMBO Rep       Date:  2005-09       Impact factor: 8.807

2.  CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.

Authors:  Xi Yin; Qian Wang; Ting Chen; Junwei Niu; Rui Ban; Jiexiao Liu; Yanling Mao; Chuanqiang Pu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Authors:  Liubov V Gushchina; Sayak Bhattacharya; Kevin E McElhanon; Jin Hyuk Choi; Heather Manring; Eric X Beck; Jenna Alloush; Noah Weisleder
Journal:  Mol Ther       Date:  2017-07-03       Impact factor: 11.454

Review 4.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

5.  Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice.

Authors:  Blythe C Dillingham; Margaret E Benny Klimek; Ramkishore Gernapudi; Sree Rayavarapu; Eduard Gallardo; Jack H Van der Meulen; Sarah Jordan; Beryl Ampong; Heather Gordish-Dressman; Christopher F Spurney; Kanneboyina Nagaraju
Journal:  J Neurol Sci       Date:  2015-06-24       Impact factor: 3.181

6.  Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo.

Authors:  Joseph A Roche; Richard M Lovering; Robert J Bloch
Journal:  Neuroreport       Date:  2008-10-29       Impact factor: 1.837

7.  Dysfunction of dysferlin-deficient hearts.

Authors:  Katrin Wenzel; Christian Geier; Fatimunnisa Qadri; Norbert Hubner; Herbert Schulz; Bettina Erdmann; Volkmar Gross; David Bauer; Ralf Dechend; Rainer Dietz; Karl Josef Osterziel; Simone Spuler; Cemil Ozcelik
Journal:  J Mol Med (Berl)       Date:  2007-09-09       Impact factor: 4.599

8.  Therapeutic exon skipping for dysferlinopathies?

Authors:  Annemieke Aartsma-Rus; Kavita H K Singh; Ivo F A C Fokkema; Ieke B Ginjaar; Gert-Jan van Ommen; Johan T den Dunnen; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

9.  Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.

Authors:  Sree Rayavarapu; Jack H Van der Meulen; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju; Susan M Knoblach
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

10.  A novel method for subarachnoid hemorrhage to induce vasospasm in mice.

Authors:  Tamer Altay; Saksith Smithason; Nina Volokh; Peter A Rasmussen; Richard M Ransohoff; J Javier Provencio
Journal:  J Neurosci Methods       Date:  2009-07-01       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.